Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono
{"title":"Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis.","authors":"Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono","doi":"10.31557/APJCP.2024.25.12.4115","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express the estrogen receptor (ER), the progesterone receptor (PR), or the human epidermal growth factor receptor 2 (HER2). TNBC has limited treatment targets, including the androgen receptor (AR). However, the therapeutic strategies-based AR expression in TNBC remains uncertain. The aim of this study is to compare the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus receptor-negative patients.</p><p><strong>Methods: </strong>A systematic search was performed through databases to search for cohort studies that compared the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus TNBC receptor-negative patients. The Mantel-Haenzel and Inverse Variance methods obtained a fixed-effects model of pooled odds or hazard ratios for the primary outcomes.</p><p><strong>Results: </strong>Fifteen cohort studies, including 2,713 patients with TNBC, were assessed. The effect of neoadjuvant chemotherapy is less superior on AR+ patients than AR- (OR = 0.60, p = 0.02). For survival outcomes, the AR+ subtype is associated with better 3-year DFS (HR = 0.93, p = 0.69) and 3-year OS (HR = 0.71, p = 0.20) compared with AR-. The statistical value is insignificant.</p><p><strong>Conclusion: </strong>The prognostic value of AR expression in TNBC is not fully understood, which is an inconclusive result.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"25 12","pages":"4115-4122"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2024.25.12.4115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express the estrogen receptor (ER), the progesterone receptor (PR), or the human epidermal growth factor receptor 2 (HER2). TNBC has limited treatment targets, including the androgen receptor (AR). However, the therapeutic strategies-based AR expression in TNBC remains uncertain. The aim of this study is to compare the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus receptor-negative patients.
Methods: A systematic search was performed through databases to search for cohort studies that compared the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus TNBC receptor-negative patients. The Mantel-Haenzel and Inverse Variance methods obtained a fixed-effects model of pooled odds or hazard ratios for the primary outcomes.
Results: Fifteen cohort studies, including 2,713 patients with TNBC, were assessed. The effect of neoadjuvant chemotherapy is less superior on AR+ patients than AR- (OR = 0.60, p = 0.02). For survival outcomes, the AR+ subtype is associated with better 3-year DFS (HR = 0.93, p = 0.69) and 3-year OS (HR = 0.71, p = 0.20) compared with AR-. The statistical value is insignificant.
Conclusion: The prognostic value of AR expression in TNBC is not fully understood, which is an inconclusive result.
期刊介绍：
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
